Microsoft Word - ACC-LT095_E_MDA-Q2'19.docx WIIK & HOEGLUND PUBLIC COMPANY LIMITED 90 CW Tower A T + 66 (2) 6128600 Business ID 0107538000151 35th Floor, Ratchadapisek Rd
www.interpharma.co.th IP_OCS/010/2562 November 10, 2019 Subject Management’s discussion and analysis for the third quarter of 2019 To President The Stock Exchange of Thailand Interpharma Public Company Limited (“the
million. In addition, the company may be subject to risks that the transaction may have a material impact on the company, in that the company may not have sufficient funds, the operating results and
Group Public Company Limited (the “Company” or “CBG”), are pleased to submit management discussion and analysis regarding consolidated financial performance and position of the Company and subsidiaries
from the investment The company will have a business that generates revenue and continuous operating results which a business that is worth the investment The hospital business is a business that can
Exchange of Thailand CAZ (Thailand) Public Company Limited (“the Company”) and its Subsidiary (“the Group”) would like to clarify the change in operating result for the second quarter ended 30 September 2019
rate Transactions with parent company Service income 40,466 47,365 114 2,281 Contract rate Revenue from advertising production 5,116 - - - Contract rate Revenue from system installation services 119,842
and the slowdown of consumption. The sales of the Company in 2016 decreased by 70 million Baht compared to the previous year. It can be sorted based on product category as follows; 1. Automotive Revenue
from q-q, mainly caused by higher revenues from High-Valued Document. THB million Q1’19 Q1’18 %Chg As Reported Total Revenues 654 313 109.0% Company 377 313 20.6% TBSP 277 - 100.0% Revenue Breakdown Mil
(expense) revenue For the 3 months period (quarter 1/2018), the Company has deferred tax expense at Baht 1.52 million which increased compared to the same quarter of prior year by Baht 1.98 million or